The PCAC: who decides which peptides are accessible

One FDA advisory committee has more influence over peptide access than most patients ever realize.

TL;DR

• The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which compounds 503A pharmacies can legally prepare.
• The PCAC advises; FDA decides. FDA's interim policy of not taking action against compounding with a substance not yet on the 503A Bulks List applies only to Category 1 substances, when other conditions are met.
• Understanding how the PCAC works helps explain why peptide availability shifts over time, sometimes with little public notice.

What it is

The PCAC — Pharmacy Compounding Advisory Committee (in plain English: a group of outside experts the FDA convenes to review compounding questions before making policy) — was established under the Drug Quality and Security Act of 2013. It typically includes pharmacists, physicians, pharmacologists, and patient advocates.

The committee reviews substances nominated for the 503A Bulks List. That list determines what drugs and compounds licensed 503A pharmacies (the smaller, patient-specific compounders) are permitted to prepare. A substance on the list can be compounded. FDA's interim policy of not taking action against compounding with a substance that is not yet on the list applies only to substances in Category 1, when other conditions are met.

How it works

Think of the PCAC as a zoning board for molecules. A city council (the FDA) sets the rules, but a specialized review panel has to evaluate each parcel (each compound) and issue a recommendation before anything is approved or rejected.

The process goes like this:

1. A substance is nominated — by a patient, physician, pharmacy, or manufacturer.
2. The FDA reviews nominations and decides which ones go to the PCAC.
3. The committee meets, reviews the evidence, and votes on a recommendation.
4. The FDA publishes a notice in the Federal Register and ultimately decides whether to add, retain, or remove the substance from the Bulks List.

The committee evaluates three things: whether the substance is safe, whether it works well enough to compound rather than use a commercially available version, and whether it serves a patient population that can't otherwise be served.

Who asks about it

People come to this topic after hearing that a peptide they were prescribed — or were hoping to try — had been reclassified or is "under FDA review." The PCAC is often the actual mechanism behind those announcements, and it's rarely explained in plain terms.

What the research says

The PCAC's recommendations are published in public meeting records on FDA.gov, so they're traceable. Notably, several peptides — including BPC-157 and TB-500 — have been nominated and reviewed under the 503A evaluation process. The committee's criteria draw from available clinical literature, so the quality and volume of peer-reviewed research on a substance directly affects its likelihood of remaining accessible.

In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026, and reviewed seven peptides. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What to know before considering it

The PCAC's work is procedural, not adversarial. The committee does not exist to restrict peptide access — it exists to ensure that compounded substances meet a safety and clinical-need standard. Its decisions reflect the available evidence at the time of review, which means more research generally supports more accessible compounds.

Any peptide you access through a licensed telehealth platform requires a valid prescription from a physician credentialed in your state. PCAC classifications affect what pharmacies can make, not what physicians can prescribe commercially when an FDA-approved equivalent exists.

The Halftime POV

At Halftime Health, we pay close attention to PCAC deliberations because our formulary depends on 503A pharmacy access. When a compound moves on or off the Bulks List, it affects what we can offer. We build our protocols around compounds with a stable regulatory history and a credible evidence base — not because we're required to, but because that's what durable telehealth looks like.

Related reading:

• 503A vs 503B compounding pharmacies explained
• What telehealth peptide prescribing actually looks like
• Hims vs Noom vs Teladoc: how telehealth GLP-1 programs differ

---

FAQ

Q: What is the PCAC? A: The PCAC (Pharmacy Compounding Advisory Committee) is a federal advisory group that evaluates whether specific drugs and compounds are appropriate for compounding at 503A pharmacies. Their recommendations influence FDA policy on which compounds remain accessible through licensed compounders.

Q: Does the PCAC control peptide access directly? A: No. The PCAC advises the FDA, but the FDA makes the final decision. The committee's recommendations carry significant weight and typically shape whether a compound ends up on the FDA's 503A Bulks List — the list that determines what 503A pharmacies can legally compound.

Q: How long does the PCAC review process take? A: Reviews vary. The committee meets periodically, and a substance can sit in queue for months or years. Nominations can come from patients, physicians, pharmacies, or manufacturers.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA Pharmacy Compounding Advisory Committee
• Drug Quality and Security Act, 2013 — Section 503A
• 503A Bulks Ingredients List — FDA.gov